Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Alliance

Neither a doctor nor a teaching hospital

Research payments

$2,454,721

545 payments

Through program year 2025, Clinical Research Alliance is reported as receiving $2,454,721 in research payments, across 545 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $880,180 385
2024 Research $365,507 20
2023 Research $139,384 15
2022 Research $71,209 48
2021 Research $40,828 26
2020 Research $408,266 29
2019 Research $549,347 22

Breakdown

Who paid Research payments · program years 2019–2025
  1. Celgene Corporation $785,110 6 payments
  2. Daiichi Sankyo Inc. $445,700 361 payments
  3. Novartis Pharmaceuticals Corporation $423,751 31 payments
  4. Merck Sharp & Dohme Corporation $336,065 7 payments
  5. AstraZeneca Pharmaceuticals LP $109,548 9 payments
  6. Kowa Research Institute, Inc. $79,815 36 payments
  7. AstraZeneca UK Limited $59,950 4 payments
  8. E.R. Squibb & Sons, L.L.C. $34,277 5 payments
  9. Ipsen Bioscience Inc $28,399 7 payments
  10. Argenx US, Inc. $27,950 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) (CC-5013-NHL-008) $453,920 2 payments
  2. Ds7300-203 $318,032 186 payments
  3. A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma(CA078-P10) $311,741 1 payment
  4. A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received $171,923 1 payment
  5. A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcHL or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma rrPMBCL $92,186 3 payments
  6. A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) $86,511 3 payments
  7. A Phase II Multicenter, Open-Label, Single-Arm Dose Escalation Study of Asciminib Monotherapy in 2Nd Line Chronic Phase - Chronic Myelogenous Leukemia $85,969 4 payments
  8. A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) $66,181 2 payments
  9. Ds6000-126 $57,074 35 payments
  10. K-877-302 $52,724 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record